NT-157

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406751

CAS#: 1384426-12-3

Description: NT157 is discontinued for commercial reason.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-08-08. Prices are subject to change without notice.

NT157 is discontinued for commercial reason.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406751
Name: NT-157
CAS#: 1384426-12-3
Chemical Formula: C16H14BrNO5S
Exact Mass: 410.9776
Molecular Weight: 412.254
Elemental Analysis: C, 46.62; H, 3.42; Br, 19.38; N, 3.40; O, 19.40; S, 7.78


Synonym: NT-157; NT 157; NT157.

IUPAC/Chemical Name: (2E)-3-(3-Bromo-4,5-dihydroxyphenyl)-N-[(3,4,5-trihydroxyphenyl)methyl]-2-propenethioamide

InChi Key: NIPUPOUEGOSAAO-OWOJBTEDSA-N

InChi Code: InChI=1S/C16H14BrNO5S/c17-10-3-8(4-11(19)15(10)22)1-2-14(24)18-7-9-5-12(20)16(23)13(21)6-9/h1-6,19-23H,7H2,(H,18,24)/b2-1+

SMILES Code: S=C(NCC1=CC(O)=C(O)C(O)=C1)/C=C/C2=CC(O)=C(O)C(Br)=C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Rampias T, Favicchio R, Stebbing J, Giamas G. Targeting tumor-stroma
crosstalk: the example of the NT157 inhibitor. Oncogene. 2016 May
19;35(20):2562-4. doi: 10.1038/onc.2015.392. Epub 2015 Oct 19. PubMed PMID:
26477311.

2: Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K,
Levitzki A, Karin M. Targeting colorectal cancer via its microenvironment by
inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.
Oncogene. 2016 May 19;35(20):2634-44. doi: 10.1038/onc.2015.326. Epub 2015 Sep
14. PubMed PMID: 26364612; PubMed Central PMCID: PMC4791217.

3: Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A, Langut Y,
Bar-Eli M, Reuveni H, Levitzki A. Targeting melanoma with NT157 by blocking Stat3
and IGF1R signaling. Oncogene. 2016 May 19;35(20):2675-80. doi:
10.1038/onc.2015.229. Epub 2015 Jun 29. PubMed PMID: 26119932.

4: Garofalo C, Capristo M, Mancarella C, Reunevi H, Picci P, Scotlandi K.
Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma
Cell Lines. Front Endocrinol (Lausanne). 2015 May 13;6:74. doi:
10.3389/fendo.2015.00074. eCollection 2015. PubMed PMID: 26029165; PubMed Central
PMCID: PMC4429561.

5: Ibuki N, Ghaffari M, Reuveni H, Pandey M, Fazli L, Azuma H, Gleave ME,
Levitzki A, Cox ME. The tyrphostin NT157 suppresses insulin receptor substrates
and augments therapeutic response of prostate cancer. Mol Cancer Ther. 2014
Dec;13(12):2827-39. doi: 10.1158/1535-7163.MCT-13-0842. Epub 2014 Sep 29. PubMed
PMID: 25267499.